Ivan Kairatov is a highly respected biopharma expert who has made significant contributions to the understanding and innovation in cancer research. With a focus on neuroblastoma, a particularly aggressive childhood cancer, his work is paving the way for new treatment strategies. In this interview,
In recent years, the intersection of biotechnology and plant biology has led to transformative developments in drug production, highlighting a pivotal turning point in the sustainable manufacturing of vital medicines. Among these advancements is the use of tobacco plants to synthesize baccatin III,
In a groundbreaking development poised to reshape medical diagnostics, Professor Kenji Suzuki and his team at the Institute of Science Tokyo have unveiled a pioneering AI model that has dramatically reduced data requirements for lung cancer diagnosis. Presented at the 2024 Annual Meeting of the
A critical patient is confronted with unsettling news: her colon cancer has returned despite rigorous chemotherapy treatment. Facing the daunting challenge of deciding the next steps, she wonders why there aren't more effective treatment options available. This poignant scenario echoes the broader
Ivan Kairatov's expertise in biopharma, particularly in advancing technologies and innovation within the industry, positions him as a leading figure in the field of biomedical imaging. With a wealth of experience in research and development, Ivan's contributions have greatly impacted the realm of
In recent times, Sanofi's Sarclisa (isatuximab) has emerged as a promising advancement in the treatment of multiple myeloma (MM), a type of blood cancer. Approximately 46,000 new cases are diagnosed annually in Europe alone, making MM the second most prevalent blood cancer after non-Hodgkin
